Does the Kidney Regenerate After Damage or Disease?

Kidneys can repair themselves after a one-time acute injury, but they cannot grow new functional units or fully regenerate tissue lost to chronic disease. The distinction matters enormously. After a temporary insult like reduced blood flow or a drug reaction, surviving kidney cells have a surprising ability to shift into a repair mode, multiply, and restore the lining of damaged tubules. But the kidney cannot manufacture new nephrons, the microscopic filtering units that do the organ’s real work, and once enough nephrons are lost or scarred over, the damage becomes permanent. That gap between “repair” and “regeneration” shapes almost everything about kidney disease.

How Surviving Cells Step In

For years, researchers debated whether the kidney harbored a hidden population of stem cells that could swoop in after injury, the way bone marrow replenishes blood cells. The evidence now points in a different direction. In mouse studies using genetic fate-mapping, scientists labeled every kidney cell and then induced injury. During repair, there was no dilution of that label, meaning no unlabeled progenitor cells migrated in to rebuild the tissue. Instead, the ordinary, fully mature cells lining the damaged tubules did the work themselves.¹

The process works roughly like this: when an acute injury kills off a stretch of tubular lining cells, the survivors revert to a less specialized state, almost like hitting a partial reset button. In that dedifferentiated form, they regain the ability to divide rapidly and spread across the bare spots, eventually re-specializing into functional tubular cells.² Multiple lineage-tracing experiments have confirmed that this regeneration is confined entirely within the tubules themselves: no outside cell type rides to the rescue.³

This is genuinely impressive for a solid organ, but it comes with a hard ceiling. The cells that survive can patch damage; they cannot build new structures from scratch. And not all kidney cell types share this talent. Podocytes, the specialized cells that wrap around the capillaries inside each glomerulus and help filter blood, cannot proliferate. Once podocytes are lost, they are gone for good, which is one reason glomerular diseases tend to be progressive.⁴

Why You Cannot Grow New Nephrons

A human kidney contains somewhere around one million nephrons per kidney at birth, though that number varies widely between individuals. The critical fact is that nephron formation shuts down around the 36th week of pregnancy and never restarts.⁵ Unlike your liver, which can regrow large portions of its mass from a remnant, or your skin, which constantly generates new layers, your kidneys are locked into whatever nephron count they had at birth. Babies born prematurely sometimes end up with fewer nephrons because that developmental window closed early, which may set them up for higher kidney-disease risk later in life.

This also explains why roughly half of all nephrons are lost through normal aging, as one large review noted, and the kidney has no way to replace them.⁶ The surviving nephrons compensate by working harder, but that extra workload itself can become damaging over decades.

What Happens When You Lose an Entire Kidney

Living kidney donors offer a natural experiment. After one kidney is removed, the remaining kidney enlarges and takes on more filtration work. In a study of healthy donors with an average age in their mid-forties, the remaining kidney’s volume increased by about 22% on average after surgery, and this compensatory growth occurred in roughly four out of five donors.⁷ The process begins within days and is driven mainly by individual cells growing larger rather than new cells dividing, a process called hypertrophy rather than hyperplasia.⁸

This is an important distinction. The kidney is not regenerating; it is inflating existing structures to carry more load. Kidney function after donation typically recovers to about 70% of the pre-donation two-kidney total, not 100%. For most healthy donors, that is more than enough. But it illustrates the organ’s fundamental constraint: it can scale up what it has, not build what it does not.

When Repair Goes Wrong

If the kidney’s built-in repair machinery is functional after acute injury, why do so many people develop chronic kidney disease? The answer lies in what researchers call maladaptive repair. When the injury is too severe, too prolonged, or repeated, the normal dedifferentiation-and-regrowth process stalls or goes sideways. Cells get stuck in a kind of limbo where they have stopped functioning normally but cannot complete their repair cycle.⁹

This failed repair triggers a cascade of problems. Persistent inflammation sets in, and specialized cells called myofibroblasts begin depositing excessive amounts of fibrous tissue, essentially replacing functional kidney architecture with scar tissue.¹⁰ The two conditions, acute kidney injury and chronic kidney disease, share overlapping pathways involving cell death, ongoing inflammation, and fibrosis, which is why a single bad episode of acute injury can become the starting point for a lifetime of declining function.¹¹

Fibrosis is the common endpoint of almost every form of chronic kidney disease regardless of the original cause, whether diabetes, high blood pressure, autoimmune conditions, or recurrent infections. Once enough of the kidney’s functional tissue has been replaced by scar, no amount of tubular cell repair can compensate.

Senescent Cells Act as a Brake on Recovery

One of the most active areas of kidney research right now involves cellular senescence, a state where damaged cells stop dividing permanently but refuse to die. These zombie-like cells accumulate in the kidney after injury and actively sabotage repair. They release a cocktail of inflammatory and fibrosis-promoting molecules that poison the surrounding tissue, blocking the proliferation of healthy cells that would otherwise patch things up.¹²

Experiments in mice have shown this directly. When researchers studied kidneys after injury, senescent tubular cells produced fibrosis-driving signals and inhibited the regenerative capacity of nearby tissue.¹³ Encouragingly, when those senescent cells were cleared using drugs called senolytics, fibrosis was reduced and repair improved. A separate study using a model of drug-induced kidney damage found that senolytic treatment reduced scarring in the kidney’s interior.¹⁴ These findings are still in animal models and have not reached clinical trials for kidney disease specifically, but the direction is promising enough that senolytics are being watched closely as a potential therapeutic strategy.

The Blood Supply Problem

Kidney tissue is extraordinarily vascular. The organ receives about 20% of total cardiac output despite making up less than 1% of body weight. When chronic disease sets in, the tiny blood vessels surrounding the tubules, called peritubular capillaries, begin to die off and are not replaced. This capillary loss starves the surrounding tissue of oxygen, creating a vicious cycle: hypoxia worsens fibrosis, and fibrosis further reduces blood supply.¹⁵

This vascular damage is one reason why chronic kidney disease tends to be a one-way street. Even if you could somehow restart the tubular repair process, the cells would not have adequate blood supply to sustain themselves. Capillary loss, along with fibrosis and tubular atrophy, is considered one of the major hallmarks that predicts how a patient’s kidney function will decline over time.

The Immune System’s Dual Role

Your immune system can either help or hinder kidney repair, depending on timing. Macrophages, the large immune cells that patrol tissues, exist in different functional states. In the early phase of injury, pro-inflammatory macrophages flood the damage site and amplify the destruction, clearing debris but also harming bystander cells. Later, if things go well, macrophages shift toward an anti-inflammatory, wound-healing profile that supports tissue repair.¹⁶

The catch is that the same wound-healing macrophages can also promote fibrosis if they overstay their welcome or if the injury environment stays abnormal. Researchers are exploring whether it might be possible to nudge macrophage behavior pharmacologically, pushing them toward repair-friendly activity at the right moment. Experimental and early translational work suggests this kind of immune modulation could become a tool to improve outcomes after acute kidney injury.¹⁷

Sex Differences in Kidney Resilience

Women generally progress to kidney failure more slowly than men, and researchers have been trying to understand why at a cellular level. Recent work using single-cell analysis in mice has pointed to a specific antioxidant defense pathway, regulated by a protein called NRF2, that is far more active in female kidney cells. This pathway protects against a form of cell death called ferroptosis, which plays a role in kidney injury. Female kidney cells showed much higher NRF2 activity than male cells, and the difference widened further under stress.¹⁸

This is not just an academic curiosity. If NRF2 activation can be mimicked or enhanced in male kidneys through drugs, it could theoretically protect against the failed repair that leads to chronic scarring in both sexes. The research identified NRF2 as a potential therapeutic target, though translating mouse findings into human treatments is still a long road.

What Zebrafish Can Do That Humans Cannot

If you want to see what real kidney regeneration looks like, zebrafish are the species to watch. Unlike mammals, zebrafish can grow entirely new nephrons after injury, essentially doing what human kidneys stopped doing in the womb.¹⁹ This ability makes them invaluable for research. If scientists can identify what molecular signals allow zebrafish kidneys to activate nephron-building programs that humans have permanently silenced, it might someday be possible to reawaken those programs in human tissue. That remains speculative, but zebrafish research has already deepened the understanding of which genetic pathways control nephron formation.

Energy and Metabolism During Repair

Kidney cells are metabolically expensive to run. Under normal conditions, tubular cells burn fatty acids as their primary fuel. After injury, surviving cells switch to a less efficient fuel source, relying more heavily on glucose breakdown. This metabolic shift is part of the acute survival response, but if it persists, it contributes to the maladaptive repair process.²⁰ Cells stuck on glycolysis cannot sustain the energy demands of a working nephron, so restoring normal metabolism is increasingly seen as a prerequisite for successful recovery.

Certain molecular signaling pathways appear to be double-edged in this context. The Wnt/β-catenin pathway, for example, promotes repair and regeneration when it activates briefly after injury, but if it stays on too long, it drives fibrosis and chronic damage.²¹ Getting the timing right on these signals is one of the central challenges for any future therapy that aims to boost kidney repair.

Emerging Approaches in Regenerative Medicine

Several experimental strategies are trying to push past the kidney’s natural repair limits. One approach uses kidney organoids, miniature kidney-like structures grown from stem cells in the lab. Researchers have managed to coax human stem cells into forming organoids that contain both filtering structures and a rudimentary collecting system, bringing them closer to the architecture of a real kidney.²² These organoids are nowhere near transplantable organs yet, but they are already useful for studying disease mechanisms and screening drugs.

A more ambitious line of work involves decellularized scaffolds. Scientists strip all the cells from a donor kidney, leaving behind just the extracellular framework, then repopulate that scaffold with new cells. In rat experiments, recellularized scaffolds were implanted, tolerated blood pressure, and even produced urine without leaking blood.²³ A separate study tested scaffolds repopulated with human stem-cell-derived cells and found they could maintain leak-free blood flow in a rodent transplant model.²⁴ Scaling this from rat-sized scaffolds to a functional human kidney remains a massive engineering challenge, but the proof of concept exists.

On the less dramatic but potentially nearer-term end, researchers are investigating whether tiny vesicles called exosomes, released by mesenchymal stem cells, could be delivered to injured kidneys to tilt the repair process in a favorable direction. These exosomes carry molecular cargo that can reduce cell death and dampen damaging signaling pathways after acute injury.²⁵ Unlike whole-cell therapies, exosomes are easier to manufacture, store, and dose, which makes them attractive for clinical development even though human trials are still in early stages.

Diabetes and the Oxygen-Starved Tubule

Diabetes is the leading cause of chronic kidney disease worldwide, and its effect on the kidney illustrates why repair capacity alone is not enough. High blood sugar forces the kidney to reabsorb more glucose and sodium than normal, which demands extra oxygen. The proximal tubular cells end up chronically oxygen-deprived even before any visible structural damage has occurred.²⁶ This chronic hypoxia sets the stage for the kind of sustained injury that overwhelms the kidney’s repair machinery. SGLT2 inhibitors, a class of diabetes drugs that reduce glucose reabsorption in the kidney, appear to protect renal tissue in part by dialing down this oxygen demand. Their kidney-protective effects have been demonstrated even in patients without diabetes, suggesting that easing the metabolic burden on tubular cells is beneficial regardless of the underlying cause.